Publication:
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.

Simple item page
dc.contributor.authorHidalgo-Tenorio, Carmen
dc.contributor.authorCortés, Luis López
dc.contributor.authorGutiérrez, Alicia
dc.contributor.authorSantos, Jesús
dc.contributor.authorOmar, Mohamed
dc.contributor.authorGálvez, Carmen
dc.contributor.authorSequera, Sergio
dc.contributor.authorJesús, Samantha Eisabeth De
dc.contributor.authorTéllez, Franciso
dc.contributor.authorFernández, Elisa
dc.contributor.authorGarcía, Coral
dc.contributor.authorPasquau, Juan
dc.date.accessioned2023-01-25T13:38:56Z
dc.date.available2023-01-25T13:38:56Z
dc.date.issued2019
dc.description.abstractDolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness and safety of 3TC plus DTG in virologically suppressed HIV-1 patients and to conduct a pharmacoeconomic analysis.We conducted an observational, retrospective and multicenter study of HIV+ patients pretreated for at least 6 months with ART that was then simplified to 3TC + DTG for any reason. We gathered data on viral loads (VLs) during exposure to the DT, calculating the rate with VL
dc.identifier.doi10.1097/MD.0000000000016813
dc.identifier.essn1536-5964
dc.identifier.pmcPMC6708975
dc.identifier.pmid31393412
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708975/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1097/md.0000000000016813
dc.identifier.urihttp://hdl.handle.net/10668/14378
dc.issue.number32
dc.journal.titleMedicine
dc.journal.titleabbreviationMedicine (Baltimore)
dc.language.isoen
dc.organizationHospital Torrecárdenas
dc.organizationAPES Hospital de Poniente de Almería
dc.organizationHospital Universitario de Puerto Real
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario de Jaén
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Virgen del Rocío
dc.page.numbere16813
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshAdult
dc.subject.meshAnti-HIV Agents
dc.subject.meshCD4 Lymphocyte Count
dc.subject.meshCost-Benefit Analysis
dc.subject.meshDrug Therapy, Combination
dc.subject.meshEconomics, Pharmaceutical
dc.subject.meshFees, Pharmaceutical
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHIV-1
dc.subject.meshHeterocyclic Compounds, 3-Ring
dc.subject.meshHumans
dc.subject.meshLamivudine
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOxazines
dc.subject.meshPiperazines
dc.subject.meshPyridones
dc.subject.meshRetrospective Studies
dc.subject.meshViral Load
dc.titleDOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number98
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC6708975.pdf
Size:
263.06 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Torrecárdenas
SAS - Hospital de Poniente
SAS - Hospital Universitario de Jaén
SAS - Hospital Universitario de Puerto Real
SAS - Hospital Universitario Virgen de la Victoria
SAS - Hospital Universitario Virgen de las Nieves
Load more

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía